Axsome Therapeutics (AXSM) Total Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $585.3 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $585.3 million, up 29.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $585.3 million (up 29.24% YoY), and the FY2025 annual result was $524.0 million, up 24.81% from the prior year.
• Total Non-Current Liabilities came in at $585.3 million for Q1 2026 at Axsome Therapeutics, up from $524.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $585.3 million in Q1 2026 to a low of $136.0 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $353.7 million (2024), against an average of $357.5 million.
• Across the five-year window, Total Non-Current Liabilities surged 120.05% in 2023 and gained 24.81% in 2025, its largest moves.
• Axsome Therapeutics' Total Non-Current Liabilities stood at $190.8 million in 2022, then soared by 69.77% to $324.0 million in 2023, then increased by 29.59% to $419.8 million in 2024, then increased by 24.81% to $524.0 million in 2025, then advanced by 11.7% to $585.3 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $585.3 million (Q1 2026), $524.0 million (Q4 2025), and $505.7 million (Q3 2025), per Business Quant data.